In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), with a price target of $9.00. The company’s shares opened today at $2.42.
Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Adaptimmune Therapeutics, and Merck & Company. According to TipRanks, Goldstein has an average return of 0.6% and a 36.02% success rate on recommended stocks.
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.25.
ADAP market cap is currently $385M and has a P/E ratio of -2.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More on ADAP: